Childhood brain tumours are genetically distinct from adult cancers and are not a focus area for drug development. M4K Pharma is pioneering a novel open science business model to address these unprecedented “high risk” targets for a fraction of the usual cost.

In this webinar, the speakers showcase how collaboration between patient groups, charities, and academia resulted in the development of small molecule inhibitors targeting high-grade diffuse intrinsic pontine glioma (DIPG) that forms in the brainstem and has a median patient survival time of 9-12 months.

Presenters

  • Alex Bullock, PhD, Principle Investigator, Structural Genomics Consortium (SGC) at the University of Oxford
  • Owen Roberts, CEO, M4K Pharma and Nobelex Biotech